ImExHS Toekomstige groei

Future criteriumcontroles 6/6

ImExHS zal naar verwachting groeien in winst en omzet met respectievelijk 111.2% en 20.5% per jaar. De winst per aandeel zal naar verwachting groeien met 111.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 23.5% zijn.

Belangrijke informatie

111.2%

Groei van de winst

111.1%

Groei van de winst per aandeel

Healthcare Services winstgroei	20.8%
Inkomstengroei	20.5%
Toekomstig rendement op eigen vermogen	23.5%
Dekking van analisten	Low
Laatst bijgewerkt	03 Sep 2024

Recente toekomstige groei-updates

Recent updates

ImExHS Limited (ASX:IME) Might Not Be As Mispriced As It Looks

Jun 27

Improved Revenues Required Before ImExHS Limited (ASX:IME) Shares Find Their Feet

Jan 02

Winst- en omzetgroeiprognoses

ASX:IME - Toekomstschattingen van analisten en financiële gegevens uit het verleden (AUD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	41	5	N/A	6	1
12/31/2025	34	3	N/A	4	1
12/31/2024	27	-1	N/A	4	1
6/30/2024	25	-3	-2	0	N/A
3/31/2024	22	-4	-1	1	N/A
12/31/2023	20	-4	0	3	N/A
9/30/2023	18	-4	0	2	N/A
6/30/2023	17	-4	-1	1	N/A
3/31/2023	17	-3	-3	-1	N/A
12/31/2022	17	-3	-4	-2	N/A
9/30/2022	18	-3	-5	-2	N/A
6/30/2022	18	-4	-5	-3	N/A
3/31/2022	16	-4	-5	-3	N/A
12/31/2021	13	-5	-6	-3	N/A
9/30/2021	13	-4	-5	-2	N/A
6/30/2021	12	-4	-4	-2	N/A
3/31/2021	11	-4	-4	-2	N/A
12/31/2020	11	-4	-4	-1	N/A
9/30/2020	10	-5	-5	-3	N/A
6/30/2020	10	-6	-6	-4	N/A
3/31/2020	9	-6	-6	-4	N/A
12/31/2019	8	-6	-7	-4	N/A
9/30/2019	7	-6	-6	-3	N/A
6/30/2019	7	-7	-5	-3	N/A
3/31/2019	6	-6	-4	-2	N/A
12/31/2018	6	-5	-3	-2	N/A
9/30/2018	5	-3	-3	-1	N/A
6/30/2018	4	-1	-2	-1	N/A
3/31/2018	4	-1	N/A	-1	N/A
12/31/2017	4	-1	N/A	0	N/A
12/31/2016	3	0	N/A	0	N/A
12/31/2015	4	0	N/A	N/A	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat IME de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 2.6% ).

Winst versus markt: Er wordt verwacht dat IME de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat IME binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van IME ( 20.5% per jaar) zal naar verwachting sneller groeien dan de markt Australian ( 5.7% per jaar).

Hoge groei-inkomsten: De omzet van IME ( 20.5% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen IME zal naar verwachting over 3 jaar hoog zijn ( 23.5 %)

ImExHS Toekomstige groei

Future criteriumcontroles 6/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 18% to AU$1.50

ImExHS Limited Provides Revenue Guidance for the Second Half and Full Year of 2023

Price target decreased by 10% to AU$1.82

Price target decreased to AU$2.03

ImExHS Limited Revises Earnings Guidance for the Fiscal Year 2022

Consensus forecasts updated

Recent updates

New major risk - Financial position

ImExHS Limited (ASX:IME) Might Not Be As Mispriced As It Looks

ImExHS Limited, Annual General Meeting, Apr 23, 2024

ImExHS Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million.

Full year 2023 earnings released: AU$0.10 loss per share (vs AU$0.085 loss in FY 2022)

Price target decreased by 18% to AU$1.50

ImExHS Limited to Report Fiscal Year 2023 Results on Feb 29, 2024

Improved Revenues Required Before ImExHS Limited (ASX:IME) Shares Find Their Feet

First half 2023 earnings released: AU$0.055 loss per share (vs AU$0.053 loss in 1H 2022)

ImExHS Limited Provides Revenue Guidance for the Second Half and Full Year of 2023

New minor risk - Financial data availability

New major risk - Revenue and earnings growth

New minor risk - Share price stability

ImExHS Limited (ASX:IME) Screens Well But There Might Be A Catch

Full year 2022 earnings released: AU$0.085 loss per share (vs AU$0.15 loss in FY 2021)

Price target decreased by 10% to AU$1.82

Less than half of directors are independent

Price target decreased to AU$2.03

ImExHS Limited has completed a Follow-on Equity Offering in the amount of AUD 1.975112 million.

First half 2022 earnings released: AU$0.053 loss per share (vs AU$0.092 loss in 1H 2021)

ImExHS Limited to Report First Half, 2022 Results on Aug 30, 2022

ImExHS Limited Revises Earnings Guidance for the Fiscal Year 2022

Consensus forecasts updated

Less than half of directors are independent

Is ImExHS (ASX:IME) Using Too Much Debt?

Full year 2021 earnings: EPS exceeds analyst expectations

ImExHS Limited, Annual General Meeting, May 19, 2022

ImExHS Limited to Report Fiscal Year 2021 Results on Feb 28, 2022

IMEXHS Launches Aquila in the Thai Market

Consensus revenue estimates fall by 11%

ImExHS Limited Provides Consolidated Revenue Guidance for the Fiscal Year 2021

Non-Executive Chairman recently bought AU$64k worth of stock

Independent Non-Executive Director recently bought AU$59k worth of stock

Price target decreased to AU$2.48

Independent Non-Executive Director recently bought AU$99k worth of stock

Full year 2020 earnings released: AU$0.15 loss per share (vs AU$0.31 loss in FY 2019)

Market Sentiment Around Loss-Making ImExHS Limited (ASX:IME)

Independent Non-Executive Director recently bought AU$173k worth of stock

Full year 2020 earnings released: AU$0.15 loss per share (vs AU$0.32 loss in FY 2019)

ImExHS Limited to Report Fiscal Year 2020 Results on Feb 26, 2021

Did You Miss ImExHS' (ASX:IME) 60% Share Price Gain?

New 90-day high: AU$2.00

Imexhs Limited Announces Executive Changes

Independent Non-Executive Director recently bought AU$58k worth of stock

First half earnings released

ImExHS Limited announced that it expects to receive AUD 0.5 million in funding from Domatorisaro Pty Ltd

Independent Non-Executive Director recently bought AU$51k worth of stock

ImExHS Limited to Report First Half, 2020 Results on Aug 31, 2020

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven